<DOC>
	<DOCNO>NCT00309985</DOCNO>
	<brief_summary>RATIONALE : Androgens cause growth prostate cancer cell . Androgen ablation therapy may stop adrenal gland make androgen . Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether androgen-ablation therapy effective without docetaxel treat metastatic prostate cancer . PURPOSE : This randomized phase III trial study androgen-ablation therapy chemotherapy see well work compare androgen-ablation therapy alone treat patient metastatic prostate cancer .</brief_summary>
	<brief_title>Androgen Ablation Therapy With Without Chemotherapy Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate ability early chemotherapy improve overall survival patient commence androgen deprivation metastatic prostate cancer . Secondary - Determine whether early chemotherapy increase time clinical progression ( radiographic symptomatic deterioration due disease ) hormonal therapy alone . - Determine whether early chemotherapy increase time development hormone-refractory disease hormonal therapy alone . - Determine whether early chemotherapy increase time serological progression hormonal therapy alone . - Determine rate biochemical response 6 month 12 month chemohormonal arm versus hormonal therapy alone arm . - Determine frequency adverse event tolerability chemotherapy combine hormonal therapy versus hormonal therapy alone . - Determine whether postulate clinically meaningful increase disease control associate alteration overall quality life use Functional Assessment Cancer Therapy-Prostate questionnaire . - Determine ability prostate-specific antigen ( PSA ) change surrogate clinical benefit therapy overall survival . Tertiary - Determine whether protein differentially translate genome hormone-sensitive prostate cancer , prostate cancer respond hormonal therapy , hormone-refractory prostate cancer . - Determine frequency constitutive polymorphism enzyme involve steroid metabolism carcinogenic process . - Determine whether amount frequency certain carcinogenic protein prostate cancer tissue C-X-C chemokine receptor type 4 ( CXCR-4 ) manganese superoxide dismutase correlate poor prognosis . OUTLINE : This randomize , multicenter study . Patients stratify accord age ( ≥ 70 v &lt; 70 ) , ECOG performance status ( 0-1 v 2 ) , combine androgen blockade &gt; 30 day ( yes v ) , duration prior adjuvant hormonal therapy ( &gt; 12 month vs ≤ 12 month ) , concurrent bisphosphonate use ( yes v ) , volume disease ( low vs high ) . Patients randomize 1 2 treatment arm . - Arm A ( Androgen-Deprivation Therapy Docetaxel ) : Patients receive androgen-deprivation therapy ( include luteinizing hormone-releasing hormone [ LHRH ] agonist therapy , LHRH antagonist therapy , surgical castration ) . Patients also receive docetaxel intravenously ( IV ) 1 hour day 1 . Treatment docetaxel repeat every 21 day 6 course absence disease progression unacceptable toxicity . - Arm B ( Androgen-Deprivation Therapy alone ) : Patients receive androgen-deprivation therapy ( arm A ) alone . Quality life assess baseline month 3 , 6 , 9 12 . After completion study treatment , patient follow periodically 10 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<criteria>Histologically cytologically confirm prostate cancer Metastatic disease On androgendeprivation therapy &lt; 120 day Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 02 PS 2 eligible decline PS due metastatic prostate cancer Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) ≤ 2.5 time ULN Creatinine clearance ≥ 30 mL/min Prothrombin time ( PT ) international normalize ratio ( INR ) ≤ 1.5 time ULN ( unless therapeutic anticoagulation ) Partial thromboplastin time ( PTT ) ≤ 1.5 time ULN ( unless therapeutic anticoagulation ) Fertile patient must use effective contraception At least 4 week since prior major surgery recover toxicity prior randomization Prior adjuvant neoadjuvant hormonal therapy allow provide follow true : Therapy discontinue ≥ 12 month ago AND evidence disease , define 1 following : PSA &lt; 0.1 ng/dL prostatectomy plus hormonal therapy PSA &lt; 0.5 ng/dL double nadir radiotherapy plus hormonal therapy Therapy last 24 month Last depot injection must expire 24month mark Prior palliative radiotherapy allow commence within 30 day start androgen deprivation Antiandrogen therapy allow singleagent therapy ≤ 7 day medial castration prevent flare More 30 day ( 6 halflives ) ( whichever longer ) since prior participation another clinical trial Concurrent participation nontherapeutic trial allow Concurrent antiandrogen therapy ( e.g. , bicalutamide flutamide ) allow , sole hormonal therapy Prostatespecific antigen ( PSA ) level rise meet criterion progression low point start androgendeprivation therapy randomization Prior malignancy past 5 year except basal cell squamous cell carcinoma skin Other malignancy consider low potential progress ( e.g. , grade 2 , T1a transitional cell carcinoma ) may allow approve study chair Peripheral neuropathy &gt; grade 1 History severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 Active cardiac disease , include follow : Active angina Symptomatic congestive heart failure Myocardial infarction within past 6 month Prior chemotherapy adjuvant neoadjuvant set Prior hormone therapy metastatic setting Concurrent 5alpha reductase inhibitor Simultaneous enrollment Cancer Leukemia Group B ( CALGB ) 90202</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>metastatic hormone-sensitive prostate cancer</keyword>
	<keyword>docetaxel</keyword>
</DOC>